Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACROBAT ADVANCE long-term extension study of CRN00808 in acromegaly
2019-002193-31Phase 2Active
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paltusotine in acromegaly, sponsored by Crinetics Pharmaceuticals. Primary endpoints: Long-term safety and tolerability of CRN00808 and Efficacy of CRN00808 in acromegaly. Started Dec 2019; status: active.
02
Drugs
paltusotine
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2019-002193-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002193-31.